HRGN — Harvard Apparatus Regenerative Technology Share News
0.000.00%
Last trade - 00:00- $39.80m
- $39.95m
- $0.70m
Brief: Biostage Activated Mayo Clinic As The First Site For Clinical Trial In Severe Esophageal Disease
Brief: Biostage Amends CEO Employment Agreement
Brief: Biostage Inc Files For Firm Commitment Public Offering Of 1.03 Million Units - SEC Filing
Brief: Biostage Announces Appointment Of New Chief Financial Officer
Brief: Biostage Announces "Meet The Founder, New Chairman And Interim CEO" Webinar
Brief: Biostage Announces Court's Preliminary Injunction Order Requiring Its Insurance Carrier To Continue Paying For Defense
Brief: Biostage Hires David Green As Chief Executive Officer
Brief: Biostage Q2 Loss Per Share $0.37
Brief: Biostage reports third quarter results
Brief: Biostage Appoints Christine Finck To Scientific Advisory Board
Brief: Biostage enters securities purchase agreement with First Pecos
Brief: Biostage posts Q2 loss per share $0.10
Brief: Biostage announces use of its Esophageal Implant product candidate in a patient
Brief: Biostage announces agreement to conduct $3.1 mln private placement at market
Brief: Biostage reports Q1 loss per share $0.14
Brief: Biostage presents positive preclincal data
Brief: Biostage announces $8.0 million public offering
Brief: Biostage files for offering of up to $8.0 mln in shares of common stock
Brief: Biostage receives FDA orphan drug designation for Cellspan Esophageal Implant